-
公开(公告)号:US20220098276A1
公开(公告)日:2022-03-31
申请号:US17547372
申请日:2021-12-10
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/74 , A61K39/00 , C07K14/47 , C07K14/635 , C07K14/725 , C07K16/28 , C12N5/0783 , C12Q1/6886 , G01N33/574 , A61K35/17
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20220098275A1
公开(公告)日:2022-03-31
申请号:US17547315
申请日:2021-12-10
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/74 , A61K39/00 , C07K14/47 , C07K14/635 , C07K14/725 , C07K16/28 , C12N5/0783 , C12Q1/6886 , G01N33/574 , A61K35/17
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
63.
公开(公告)号:US20220009982A1
公开(公告)日:2022-01-13
申请号:US17474894
申请日:2021-09-14
Applicant: Immatics Biotechnologies GmbH
Inventor: Heiko SCHUSTER , Annika SONNTAG , Daniel Johannes KOWALEWSKI , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH , Colette SONG
IPC: C07K14/47 , C07K14/74 , C07K14/725
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20210393754A1
公开(公告)日:2021-12-23
申请号:US17390584
申请日:2021-07-30
Applicant: Immatics Biotechnologies GmbH
Inventor: Sabrina KUTTRUFF-COQUI , Toni WEINSCHENK , Jens FRITSCHE , Steffen WALTER , Norbert HILF , Oliver SCHOOR , Colette SONG , Harpreet SINGH
IPC: A61K39/00 , C07K14/47 , C07K14/705 , A61K35/17 , C07K7/06 , C07K7/08 , C07K14/74 , C07K16/28 , C12Q1/6886
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号:US20210363211A1
公开(公告)日:2021-11-25
申请号:US17377905
申请日:2021-07-16
Applicant: Immatics Biotechnologies GmbH
Inventor: Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , C07K14/74 , C07K16/30 , C07K14/725 , C12N5/0783 , C12N15/10 , A61K39/00 , C12N15/115 , G01N33/574 , A61P35/00 , C07K16/28 , A61K35/17 , C07K7/06 , C07K14/54
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20210363209A1
公开(公告)日:2021-11-25
申请号:US17371871
申请日:2021-07-09
Applicant: Immatics Biotechnologies GmbH
Inventor: Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , C07K14/74 , C07K16/30 , C07K14/725 , C12N5/0783 , C12N15/10 , A61K39/00 , C12N15/115 , G01N33/574 , A61P35/00 , C07K16/28 , A61K35/17 , C07K7/06 , C07K14/54
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20210340204A1
公开(公告)日:2021-11-04
申请号:US17371826
申请日:2021-07-09
Applicant: Immatics Biotechnologies GmbH
Inventor: Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , C07K7/06 , C12N5/0783 , A61P35/00 , C12N15/115 , C07K14/725 , G01N33/574 , A61K39/00 , C07K16/28 , C07K16/30 , A61K35/17 , C07K14/54 , C07K14/74 , C12N15/10
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20210330772A1
公开(公告)日:2021-10-28
申请号:US17366958
申请日:2021-07-02
Applicant: Immatics Biotechnologies GmbH
Inventor: Colette SONG , Linus BACKERT , Heiko SCHUSTER , Daniel Johannes KOWALEWSKI , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
69.
公开(公告)号:US20210283231A1
公开(公告)日:2021-09-16
申请号:US17333994
申请日:2021-05-28
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , C07K7/08 , C12N15/115 , C12N5/0783 , C07K14/71 , C07K14/725 , C07K16/28 , C12Q1/6886 , C07K16/18 , G01N33/574 , C07K14/47 , C07K16/30 , C07K7/06 , C07K14/72 , C12N9/12 , C07K16/38 , C07K14/81 , C07K16/40 , C12N9/02 , C07K14/705 , G16B25/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20210275652A1
公开(公告)日:2021-09-09
申请号:US17314492
申请日:2021-05-07
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Colette SONG
IPC: A61K39/00 , G16B25/00 , C07K14/47 , A61P35/00 , A61K35/17 , C07K16/18 , C12N5/0783 , C12N15/115 , C07K14/74 , C07K16/28 , C07K16/30
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-